Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Change in Receivables (2016 - 2025)

International Stem Cell (ISCO) has disclosed Change in Receivables for 16 consecutive years, with -$86000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 33.85% to -$86000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $335000.0, a 830.56% increase, with the full-year FY2024 number at $484000.0, up 379.77% from a year prior.
  • Change in Receivables was -$86000.0 for Q3 2025 at International Stem Cell, down from $250000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $378000.0 in Q4 2024 to a low of -$239000.0 in Q2 2022.
  • A 5-year average of $32210.5 and a median of $34000.0 in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 784.62% in 2024; the steepest drop was 622.22% in 2024.
  • International Stem Cell's Change in Receivables stood at $176000.0 in 2021, then skyrocketed by 81.82% to $320000.0 in 2022, then tumbled by 121.88% to -$70000.0 in 2023, then soared by 640.0% to $378000.0 in 2024, then plummeted by 122.75% to -$86000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Change in Receivables are -$86000.0 (Q3 2025), $250000.0 (Q2 2025), and -$207000.0 (Q1 2025).